Clinical Trial Update: Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the addition of bortezomib (VELCADE) to RCHOP for previously untreated Non-Germinal B-Cell-like Diffuse Large B-Cell Lymphoma; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-germinal B-cell-like Diffuse Large B-cell Lymphoma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) | Phase 2 | Status: COMPLETED | Results posted: 2017-01-11